LENZ — Lenz Therapeutics Balance Sheet
0.000.00%
- $813.11m
- $604.08m
- 31
- 25
- 70
- 37
Annual balance sheet for Lenz Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19.8 | 377 | 268 | 184 | 209 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 21.1 | 382 | 275 | 188 | 212 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.46 | 18.1 | 28.2 | 0.321 | 1.99 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 22.6 | 402 | 322 | 188 | 215 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 32 | 12.1 | 13 | 4.8 | 10.4 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 32.4 | 17.9 | 25.6 | 4.87 | 11.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -9.8 | 384 | 296 | 184 | 204 |
Total Liabilities & Shareholders' Equity | 22.6 | 402 | 322 | 188 | 215 |
Total Common Shares Outstanding |